MAPT and Alzheimer disease: Thus, SCF+G-CSF treatment in aged APP/PS1 mice ameliorates or reverses each central feature of AD neuropathology: aggregated Aβ, Aβ-induced aggregation of tau, neuroinflammation, and the degeneration of neural processes and synaptic connections [22].